Biogen (BIIB) Short-term Investments (2009 - 2026)

Biogen's Short-term Investments history runs 17 years deep, the most recent figure standing at $900.0 million for Q1 2026.

• In Q1 2026, Short-term Investments changed N/A year-over-year to $900.0 million; the TTM figure through Mar 2026 stood at $900.0 million (changed N/A YoY), while the FY2025 annual figure was $807.2 million, changed N/A from the prior year.
• Short-term Investments was $900.0 million for Q1 2026 at Biogen, up from $807.2 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $3.5 billion in Q2 2023 to a low of $97.6 million in Q3 2025.
• Historically, Short-term Investments has averaged $1.6 billion across 4 years, with a median of $1.5 billion in 2022.
• Biggest YoY gain for Short-term Investments was 64.37% in 2022; the steepest drop was 12.58% in 2022.
• A 4-year view of Short-term Investments shows it stood at $1.5 billion in 2022, then surged by 134.85% to $3.5 billion in 2023, then plunged by 76.67% to $807.2 million in 2025, then climbed by 11.5% to $900.0 million in 2026.
• The last three Short-term Investments figures came in at $900.0 million (Q1 2026), $807.2 million (Q4 2025), and $97.6 million (Q3 2025), per Business Quant data.